MedPath

PERJETA

These highlights do not include all the information needed to use PERJETA safely and effectively. See full prescribing information for PERJETA. PERJETA (pertuzumab) injection, for intravenous use Initial U.S. Approval: 2012

Approved
Approval ID

17f85d17-ab71-4f5b-9fe3-0b8c822f69ff

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Oct 20, 2020

Manufacturers
FDA

Genentech, Inc.

DUNS: 080129000

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Pertuzumab

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code50242-145
Application NumberBLA125409
Product Classification
M
Marketing Category
C73585
G
Generic Name
Pertuzumab
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateOctober 20, 2020
FDA Product Classification

INGREDIENTS (6)

HISTIDINEInactive
Code: 4QD397987E
Classification: IACT
PERTUZUMABActive
Quantity: 30 mg in 1 mL
Code: K16AIQ8CTM
Classification: ACTIB
ACETIC ACIDInactive
Code: Q40Q9N063P
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
SUCROSEInactive
Code: C151H8M554
Classification: IACT
POLYSORBATE 20Inactive
Code: 7T1F30V5YH
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

PERJETA - FDA Drug Approval Details